Skip to Content

Saratoga Health & Biotechnology I SBHIX

Medalist Rating as of | See Saratoga Investment Hub
  • NAV / 1-Day Return 22.91  /  +0.04 %
  • Total Assets 11.6 Mil
  • Adj. Expense Ratio
    2.350%
  • Expense Ratio 2.350%
  • Distribution Fee Level High
  • Share Class Type Institutional
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 250
  • Status Open
  • TTM Yield
  • Turnover 58%

USD | NAV as of Apr 24, 2024 | 1-Day Return as of Apr 24, 2024, 10:22 PM GMT+0

Morningstar’s Analysis SBHIX

Will SBHIX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Saratoga Health& Biotechnology I's Average People Pillar and Process Pillar ratings are n't enough to prevent other weaknesses from sending this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBHIX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 41.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Regeneron Pharmaceuticals Inc

5.34 647,280
Healthcare

Cencora Inc

4.99 604,314
Healthcare

McKesson Corp

4.52 547,480
Healthcare

Amgen Inc

4.50 545,469
Healthcare

The Cigna Group

3.80 460,848
Healthcare

Cardinal Health Inc

3.76 455,535
Healthcare

Elevance Health Inc

3.76 455,135
Healthcare

Tenet Healthcare Corp

3.70 448,539
Healthcare

Thermo Fisher Scientific Inc

3.61 437,898
Healthcare

Intuitive Surgical Inc

3.56 431,872
Healthcare